Journal article

Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol

Marlon Perera, John El Khoury, Vidyasagar Chinni, Damien Bolton, Liang Qu, Paul Johnson, Jason Trubiano, Christine F McDonald, Daryl Jones, Rinaldo Bellomo, Oneel Patel, Joseph Ischia

BMJ Open | BMJ PUBLISHING GROUP | Published : 2020


INTRODUCTION: SARS-CoV-2 (COVID-19) has caused an international pandemic of respiratory illness, resulting in significant healthcare and economic turmoil. To date, no robust vaccine or treatment has been identified. Elemental zinc has previously been demonstrated to have beneficial effects on coronaviruses and other viral respiratory infections due to its effect on RNA polymerase. Additionally, zinc has well-demonstrated protective effects against hypoxic injury-a clear mechanism of end-organ injury in respiratory distress syndrome. We aimed to assess the effect of high-dose intravenous zinc (HDIVZn) on SARS-CoV-2 infection. The end of study analyses will evaluate the reduction of impact of ..

View full abstract